Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
暂无分享,去创建一个
A. Drilon | A. Shaw | S. Ou | M. Ahn | R. Doebele | D. Hyman | D. Camidge | Dong-Wan Kim | B. Cho | Jeeyun Lee | D. Zhai | E. Rogers | V. Zhu | Jessica J. Lin | J. Whitten | J. Cui | Zhongdong Huang | W. Deng | S. Stopatschinskaja | John K. C. Lim | Judy Nguyen | Juliet Liu | John K. C. Lim | John K. C. Lim | John K. C. Lim | D. Camidge | Sai-Hong Ignatius Ou | Byoung Chul Cho | Jessica J. Lin | John K Lim | David M. Hyman | Alice T. Shaw
[1] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[2] A. Shaw,et al. Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial , 2017, The Lancet. Oncology.
[3] A. Shaw,et al. Recent Advances in Targeting ROS1 in Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] B. Taylor,et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.
[5] A. Drilon,et al. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance , 2017, Nature Reviews Clinical Oncology.
[6] A. Iafrate,et al. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. , 2017, JCO precision oncology.
[7] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[8] M. Ahn,et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Drilon,et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.
[10] A. Shaw,et al. Targeting ALK: Precision Medicine Takes on Drug Resistance. , 2017, Cancer discovery.
[11] Lauren L. Ritterhouse,et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. , 2016, Cancer discovery.
[12] Lauren L. Ritterhouse,et al. Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .
[13] M. Ladanyi,et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] M. Ladanyi,et al. A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer , 2015, Clinical Cancer Research.
[15] Gang Li,et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.
[16] M. McTigue,et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations , 2015, Proceedings of the National Academy of Sciences.
[17] Dong-Wan Kim,et al. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[18] J. Engelman,et al. Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer , 2014, Clinical Cancer Research.
[19] D. Hsiang,et al. Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] Makoto Nishio,et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. , 2014, Cancer discovery.
[21] Jeffrey A. Engelman,et al. Tyrosine kinase gene rearrangements in epithelial malignancies , 2013, Nature Reviews Cancer.
[22] Mari Mino-Kenudson,et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. , 2013, The New England journal of medicine.
[23] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[24] Jeffrey W. Clark,et al. Crizotinib in ROS 1-Rearranged Non – Small-Cell Lung Cancer , 2014 .